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Background: Several clinical trials have demonstrated the efficacy and safety of osimertinib in advanced non-
small-cell lung cancer (NSCLC). However, there is significant unexplained variability in treatment outcome.
Methods: Observational prospective cohort of 22 pre-treated patients with stage IV NSCLC harboring 
the epidermal growth factor receptor (EGFR) p.T790M resistance mutation and who were treated with 
osimertinib. Three hundred and twenty-six serial plasma samples were collected and analyzed by digital PCR 
(dPCR) and next-generation sequencing (NGS).
Results: The median progression-free survival (PFS), since the start of osimertinib, was 8.9 [interquartile 
range (IQR): 4.6–18.0] months. The median treatment durations of sequential gefitinib + osimertinib, 
afatinib + osimertinib and erlotinib + osimertinib treatments were 30.1, 24.6 and 21.1 months, respectively. 
The p.T790M mutation was detected in 19 (86%) pre-treatment blood samples. Undetectable levels of the 
original EGFR-sensitizing mutation after 3 months of treatment were associated with superior PFS (HR: 
0.2, 95% CI: 0.05–0.7). Likewise, re-emergence of the original EGFR mutation, alone or together with the 
p.T790M mutation was significantly associated with shorter PFS (HR: 8.8, 95% CI: 1.1–70.7 and HR: 5.9, 
95% CI: 1.2–27.9, respectively). Blood-based monitoring revealed three molecular patterns upon progression 
to osimertinib: sensitizing+/T790M+/C797S+, sensitizing+/T790M+/C797S–, and sensitizing+/T790M–/
C797S–. Median time to progression in patients showing the triplet pattern (sensitizing+/T790M+/C797S+) 
was 12.27 months compared with 4.87 months in patients in whom only the original EGFR sensitizing was 
detected, and 2.17 months in patients showing the duplet pattern (sensitizing+/T790M+). Finally, we found 
that mutations in exon 545 of the PIK3CA gene were the most frequent alteration detected upon disease 
progression in patients without acquired EGFR-resistance mutations.
Conclusions: Different molecular patterns identified by plasma genotyping may be of prognostic 
significance, suggesting that the use of liquid biopsy is a valuable approach for tumor monitoring.
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cancer (NSCLC); osimertinib
Submitted Sep 20, 2019. Accepted for publication Mar 13, 2020.
doi: 10.21037/tlcr.2020.04.01
View this article at: http://dx.doi.org/10.21037/tlcr.2020.04.01
540
533Translational Lung Cancer Research, Vol 9, No 3 June 2020
  Transl Lung Cancer Res 2020;9(3):532-540 | http://dx.doi.org/10.21037/tlcr.2020.04.01© Translational Lung Cancer Research. All rights reserved.
Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) have been the standard of care for 
patients with advanced EGFR-mutant non-small-cell lung 
cancer (NSCLC) (1,2). However, most patients progress 
within 1 to 2 years (3). The EGFR p.T790M mutation 
is the most common resistance mechanism to first- and 
second-generation EGFR TKIs (4). Osimertinib, a third-
generation TKI, has demonstrated its clinical efficacy 
in NSCLC tumors harboring the p.T790M mutation at 
disease progression after treatment with first- or second-
generation EGFR TKIs (5). Moreover, in the randomized 
phase III FLAURA trial, osimertinib exceeded the standard 
of care gefitinib or erlotinib in treatment-naive NSCLC 
patients harboring EGFR exon 19 deletions and the p.L858R 
point mutation, giving rise to a significant improvement 
in median progression-free survival (PFS) compared with 
standard TKIs (6).
Nevertheless, acquired EGFR mutations conferring 
osimertinib resistance invariably emerge, such as the 
p.C797S mutation, which accounts for approximately 
20–40% of the cases (7,8). Other resistance mechanisms 
have also been described (9,10). A better understanding 
of the diversity of mechanisms by which tumors acquire 
resistance to third-generation EGFR inhibitors is of 
particular relevance to the better clinical management of 
patients, making the analysis of circulating tumor DNA 
(ctDNA) during disease progression an attractive means of 
deriving new insights into tumor biology at different stages 
of the disease. In this paper, we describe an observational 
prospective cohort of 22 unselected patients treated with 
osimertinib with a median follow-up of 62 months. In 
addition, ctDNA analysis was performed on 326 samples 
collected throughout the course of disease.
Methods
Study cohort
The present observational study was conducted on 22 
prospectively enrolled patients. Patients were followed from 
their diagnosis of stage IV disease. The study was approved 
by the Hospital Puerta de Hierro Ethics Committee and 
was conducted in accordance with the precepts of the Code 
of Ethics of The World Medical Association (Declaration 
of Helsinki). Written informed consent was obtained from 
all patient. Briefly, eligible patients were males and females 
with a pathologically confirmed diagnosis of stage IIIB–IV 
NSCLC tumor harboring an EGFR mutation, who were 
treated with a TKI, and who were candidates for receiving 
osimertinib. A complete staging workup was performed 
prior to recruitment. Data on demographic characteristics, 
clinicopathological features, tumor mutational status, 
vital status, disease status, drug dose adjustments and 
discontinuation of medication were collected in the 
study’s electronic database. Computed tomography (CT) 
measurements and magnetic resonance imaging (MRI) were 
obtained as clinically indicated. The clinical response was 
evaluated according to RECIST v1.1 criteria combined 
with a blinded medical judgment about the benefits of the 
treatment. Additionally, whole-body 18F-fluoro-2-deoxy-
D-glucose positron emission tomography (18FDG-PET) 
CT scans were performed as clinically indicated.
Laboratory procedures
Three hundred and twenty-six whole blood samples were 
collected in an 8.5 mL PPT™ tube (Becton Dickinson 
Franklin Lakes, NJ, USA) containing a gel barrier to 
separate the plasma after centrifugation. Samples were 
processed as previously described (11-13). Briefly, after 
two consecutive centrifugations, cfDNA was isolated from 
plasma using the Maxwell® RSC (MR) ccfDNA Plasma Kit 
(Promega Corporation, Madison, WI, USA). The original 
EGFR-sensitizing mutation, and the p.T790M and p.C797S 
resistant mutations were analyzed by digital PCR (dPCR). 
Specifically, cfDNA was analyzed using commercially 
available predesigned TaqMan® Liquid Biopsy dPCR 
assays as well as custom TaqMan® assays in a QuantStudio® 
3D Digital PCR System (Applied Biosystems, South San 
Francisco, CA, USA). dPCR reactions were carried out in a 
final volume of 18 μL and using 8.55 μL of cfDNA template. 
Subsequently, 14.5 μL were loaded into a QuantStudio 
3D Digital PCR 20K chip. The cycling conditions were as 
follows: initial denaturation at 96 ℃ for 10 min, followed 
by 40 cycles at 56 ℃ for 2 min, and 98 ℃ for 30 s, a step of 
72 ℃ for 10 min, and finally samples were maintained at 
22 ℃ for at least 30 min. Chip fluorescence was measured 
twice. Results were analyzed with QuantStudio® 3D 
AnalysisSuiteTM Cloud Software. The automatic call 
assignments for each data cluster were manually adjusted 
when needed. The result of the assay is reported as the ratio 
of mutant DNA molecules relative to the sum of mutant and 
wild-type (wt) DNA molecules. A negative and a positive 
control DNA were included in every run.
Libraries were prepared using the OncomineTM Pan-
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Cancer Cell-Free Assay (Thermo Fisher, Palo Alto, CA, 
USA) according to manufacturer’s instructions. All the 
purifications were done using AMPure XP magnetic 
beads (Beckman Coulter, Inc., Brea, CA, USA). Library 
quantification was performed using the Ion Library 
TaqMan® Quantitation kit (Thermo Fisher, Palo Alto, CA, 
USA) in a StepOnePlusTM qPCR machine (Thermo Fisher, 
Palo Alto, CA, USA). The individual libraries were diluted 
to a final concentration of 100 pM. The final barcoded 
libraries were pooled and adjusted to a final concentration 
of 50 pM. Template preparation and chip loading were 
carried out on an Ion ChefTM System (Thermo Fisher, Palo 
Alto, CA, USA). Eight samples were loaded onto an Ion 
550TM chip. Finally, Ion 550TM chips were sequenced in an 
Ion S5TM Sequencer (Thermo Fisher, Palo Alto, CA, USA).
Raw sequencing data were analyzed using Torrent Suite 
Software (v5.10.0). Sequencing coverage was analyzed using 
the Coverage Analysis (v.5.10.0.3) plug-in (Thermo Fisher, 
Palo Alto, CA, USA). Raw reads were aligned to the human 
reference genome hg19.
Variant calling, annotation and filtering were carried 
out on the Ion Reporter (v5.10) platform using the 
Oncomine TaqSeq Pan-Cancer Liquid Biopsy workflow 
(v5.10). The clinical significance of somatic variants was 
determined according to the Standards and Guidelines 
for the Interpretation and Reporting of Sequence Variants 
in Cancer (14). Mutations with an allele frequency (AF) 
greater than or equal to 0.1% were considered positive.
Statistical analysis
Discrete variables are presented as frequencies and 
proportions, and continuous variables as means and 
standard deviations (SDs), unless otherwise specified. The 
median follow-up was estimated by the reverse Kaplan-
Meier method (15). Overall survival (OS) and PFS were 
evaluated using the Kaplan-Meier survival function and 
Cox proportional hazards models. For OS analysis, time 
from the start of treatment with osimertinib to death or 
last follow-up was measured. PFS was defined as the time 
between the start of osimertinib treatment and disease 
progression, as assessed by RECIST criteria, or all-cause 
death. Patients who were alive on the last date of assessment 
and who had not experienced any event were censored at 
that time. Time to treatment discontinuation (TTD) of 
targeted therapy was defined as the time between the date 
when first-line treatment with a TKI began to the date 
of osimertinib discontinuation or death. Similarly, time 
to osimertinib discontinuation was also analyzed. Hazard 
ratios (HRs) were calculated from univariate Cox models. 
Significance was concluded for P values less than 0.05. 




The study cohort included 22 patients. Clinico-pathological 
characteristics of the study population are presented in Table 1. 
The median age at diagnosis was 65 (range, 41–75) years. We 
found an unusually high prevalence of tobacco consumption, 
whereby 41% (9/22) of the patients were smokers (3/22) 
or former-smokers (6/22), with a mean consumption of 35 
(SD: 28.5) pack-years. According to the pathologist’s report, 
54.5% of the cases (12/22) harbored exon 19 deletions. In 
one case, a deletion in exon 19 co-occurred with the p.S768I 
mutation in exon 20. In addition, 45.5% (10/22) harbored 
the point mutation p.L858R in exon 21. These frequencies 
Table 1 Clinico-pathological features of the study population
Feature Grouping N %
Age (years) Median 65.2 –
Sex Male 9 41
Female 13 59








Histology Adenocarcinoma 22 100




EGFR mutation Deletion exon 19 12 55
L858R 10 45






EGFR, epidermal growth factor receptor.
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are as expected, based on previously published data. No 
significant differences were observed in OS and PFS with 
respect to the original EGFR-sensitizing mutation. At the 
start of osimertinib treatment, patients had a median of 
three metastatic sites, the most frequent locations being the 
lung (73%), the bone (64%), the pleura (59%), the central 
nervous system (23%) and the peritoneum (14%). The 
ECOG Performance Status varied from 0 to 2. Patients 
with an ECOG Performance Status of 0 exhibited improved 
OS (P=0.026).
The median follow-up was 62 months. During the 
study, 12 deaths were recorded and progressive disease 
(PD) to osimertinib was observed in 16 patients (73%). 
Interestingly, in one patient, a transformation from NSCLC 
to small-cell lung cancer (SCLC) was observed upon disease 
progression. Median PFS, since the start of osimertinib 
treatment, was 8.9 [interquartile range (IQR): 4.6–18.0] 
months, whereas median OS, since osimertinib initiation, 
was 20.7 (IQR: 8.8–27.7) months. Osimertinib was used as a 
second-line treatment in 11 (50%) patients, while 11 (50%) 
patients had received two or more lines of treatment prior 
to that with osimertinib. As expected, the latter group of 
patients had a significantly poorer outcome in terms of PFS 
and OS than the former (P<0.004 and 0.020, respectively). 
Clinical objective response rates (RECIST criteria) were 
observed in 14 (64%) patients. Oligoprogressive disease 
(oligo-PD) was noted in 9 (41%) patients, and in 7 of whom 
(78%) osimertinib was maintained for a median of 3.8 (IQR: 
1.2–9.1) months beyond oligo-PD.
Median treatment durations of sequential gefitinib 
+ osimertinib, afatinib + osimertinib and erlotinib + 
osimertinib were 30.1, 24.6 and 21.1 months, respectively, 
indicating that time on targeted therapy was longest in 
patients treated with the combination gefitinib + osimertinib 
combination. However, no significant differences were 
observed in OS and PFS according to first TKI treatment 
(afatinib, gefitinib, erlotinib). Figure 1 shows the times on 
targeted therapy and the time under osimertinib treatment 
for each patient.
Considering toxicity, 12 patients reported adverse 
events, 82.6% of which were mild (G1). The most 
frequent toxicities were neutropenia (9%), diarrhea (9%), 
hypertransaminasemia (9%) and asthenia (9%). Only one 
G3 event was recorded (asymptomatic hyperamylasemia).
0 12 24 36 48 60
Osi starts Osi ends Afatinib Gefitinib Erlotinib Other Death
Figure 1 Swimmer chart showing the individual treatment responses since the start of first TKI therapy. Blue, red and orange bars 
correspond to patients who were treated with afatinib, erlotinib and gefitinib, respectively, in first-line treatment prior to osimertinib 
treatment. Initiation of osimertinib treatment is denoted by a purple triangle. TKI, tyrosine kinase inhibitor.
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Longitudinal ctDNA monitoring
To analyze the evolution of these tumors throughout the 
course of treatment, EGFR somatic mutations within 
ctDNA were prospectively collected from 326 samples and 
analyzed by dPCR. A blood sample obtained before starting 
osimertinib treatment was available for all patients. At 
baseline, the p.T790M mutation was detected in 19 (86%) 
patients, with a median AF of 4.11% (minimum 0.1%; 
maximum 37.7%). In the other three cases, the p.T790M 
mutation was detected only in the re-biopsy (N=2) and in 
the cerebrospinal fluid (N=1). Noteworthy, two of these 
plasma-negative T790M patients each had metastases 
exclusively at the brain level. The original EGFR-sensitizing 
mutation was detected in all pre-treatment samples. 
Neither p.T790M AF nor the original EGFR-sensitizing 
mutation AF at the start of treatment predicted a survival 
benefit from osimertinib. Nevertheless, ctDNA levels 
across serial plasma samples were correlated with treatment 
responses. Specifically, undetectable levels of the original 
EGFR-sensitizing mutation after 3 months of osimertinib 
treatment were associated with improved PFS (HR: 0.19, 
95% CI: 0.05–0.7). Similarly, patients in whom plasma 
levels of the original EGFR-sensitizing decreased after 
3 months had a better prognosis in terms of PFS (HR: 0.14, 
95% CI: 0.23–0.86). On the other hand, re-emergence 
of the original EGFR mutation, alone or together with 
the p.T790M mutation, was significantly associated with 
shorter PFS (HR: 8.8, 95% CI: 1.1–70.7 and HR: 5.9, 
95% CI: 1.2–27.9, respectively), indicating that ctDNA 
quantification is informative in terms of prognosis also in 
this group of patients.
Molecular patterns upon disease progression
In order to assess the frequency of the p.C797S (c.2389T>A 
and c.2390G>C) mutation at the time of osimertinib 
progression in our population, dPCR was performed in 
all samples collected at osimertinib progression (N=16) 
(Figure 2A). At this time, the p.C797S mutation was found 
along with the p.T790M mutation as well as the original 
EGFR-sensitizing mutation in 3 (19%) patients (two cases 
with the p.L858R mutation and one with a deletion in exon 
19). Specifically, two cases harbored the c.2390 G>C mutation 
and one featured the c.2389T>A mutation. Remarkably, 
dPCR analysis did not identify the p.C797S mutation in 
any of the previously collected samples, indicating that cells 
with this mutation were positively selected over the course 
of therapy. The p.C797S mutation was detected at a lower 
AF than p.T790M mutation levels, which, at the same time, 
were lower than the sensitizing mutation AF (Figure 2B). 
Interestingly enough, patients showing this “triplet pattern” 
(sensitizing+/T790M+/C797S+) tended to exhibit longer 
PFS and OS than patients who did not (P=0.1, Figure S1). 
In 2 patients (12.5%), plasma levels of the original EGFR-
sensitizing mutation were again detected at the time of disease 
progression alongside the p.T790M mutation (Figure 2C). 
This “duplet pattern” (sensitizing+/T790M+) was detected 
in patients with a high tumor load. Finally, in the other 11 
(69%) cases, there was a prominent increase in the original 
EGFR-sensitizing mutation, with null or residual levels of 
the p.T790M mutation detected (Figure 2D), suggesting that 
osimertinib was able to eliminate the p.T790M-mutated 
clone in this subset of patients (sensitizing+), even though the 
tumor was able to become resistant to treatment. The median 
time to progression in patients showing the triplet pattern 
(sensitizing+/T790M+/C797S+) was 12.27, 4.87 months 
in patients in whom only the original EGFR-sensitizing 
mutation was detected, and 2.17 months in patients with 
the duplet pattern (sensitizing+/T790M+). Figure S2 shows 
how early the appearance of the resistance mechanism was 
detected during ctDNA monitoring.
Next-generation sequencing (NGS) analysis upon 
osimertinib progression
ctDNA collected at the time of disease progression was 
available from seven patients for NGS analysis. In this subset 
of patients, PIK3CA mutations were the alterations most 
frequently detected upon disease progression, being found 
in four patients. Specifically, we identified the p.E545K 
mutation in one patient (Table 2). The analysis of previous 
plasma samples by dPCR revealed that this mutation 
was not present at the start of the treatment (Figure 3). 
Likewise, the mutation p.E545A was detected at disease 
progression in three patients. Curiously, we detected the 
p.S464L mutation in the EGFR gene in a patient who was 
treated with cetuximab plus afatinib prior to osimertinib 
therapy. In addition, the p.A750P mutation in the EGFR 
gene was found in another patient who harbored the 
deletion in exon 19 p.L747_A750>P. Retrospective analysis 
of plasma samples revealed that the A750P mutation was 
also present at the start of osimertinib treatment although 
at a very low AF. Finally, an EGFR copy-number gain was 
detected by NGS in one case. However, this alteration 
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could not be confirmed by any other alternative technique.
On the other hand, we found that the median TTD 
was 8.7 (IQR: 2.8–10.1) months in patients whose tumors 
harbored co-mutations in TP53, compared with 18 (IQR: 
7.8–28.2) months in patients whose tumors were negative 
for TP53 mutations. However, the difference noted was not 
statistically significant, given the small sample size.
Discussion
There is growing evidence of the usefulness of liquid biopsy 
as an effective tool for biomarker testing and treatment 
Figure 2 Different molecular patterns upon disease progression. (A) Two-dimensional fluorescence plot. The C797S (c.2390G>C) mutation 
is labelled with FAM (blue data points), whereas the wild-type is labelled with VIC (red data points); (B,C,D) longitudinal quantitative 
analyses of EGFR mutations in plasma samples. ctDNA levels (AF%) of patients with a triplet, duplet and single pattern (B, C and D 
respectively) are presented. Therapies are denoted by different-colored shading. PD, ascertained by CT scans at different times, is indicated 
with a red triangle. EGFR, epidermal growth factor receptor; ctDNA, circulating tumor DNA; AF, allele frequency; PD, progressive disease; 
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Table 2 Molecular alterations detected in ctDNA upon progression to osimertinib treatment
Number of cases Gene Genomic alteration Method
3 EGFR p.C797S dPCR
3 PIK3CA p.E545A NGS, dPCR
1 PIK3CA p.E545K NGS, dPCR
1 EGFR p.A750P NGS, dPCR
1 EGFR p.S464L NGS, dPCR
1 EGFR Amplification NGS
ctDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; dPCR, digital PCR.
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monitoring. In the present study, the p.T790M mutation 
was detected in the plasma of 19 (86%) patients at baseline, 
supporting the clinical utility of liquid biopsies for decision-
making about treatment. Nevertheless, the possibility of a 
false-negative result should be ruled out using tumor tissue 
obtained by biopsy (16). The reported sensitivities of the 
different assays for EGFR mutation detection using cfDNA 
from advanced NSCLC patients vary as much as from 30% 
to 100% (17). Although the cohort presented in this study is 
rather limited our results supports the usefulness of dPCR 
for plasma p.T790M testing. On the other hand, levels of 
the original EGFR-sensitizing mutation after 3 months 
of osimertinib treatment were of prognostic significance. 
Noteworthy, the effect size was substantive (HR: 0.19, 95% 
CI: 0.05–0.7). Several studies have reported that EGFR 
mutation tracking correlates with treatment outcome 
(11,12). However, it is important to mention that in the 
case of NSCLC patients resistant to first/second-generation 
EGFR-TKIs, treated with osimertinib, only the original 
EGFR-sensitizing mutation is informative for monitoring 
purposes. According to our data, a complete clearance of 
the p.T790M mutation was found in 69% of the patients 
with PD, and therefore, the p.T790M mutation is not useful 
in monitoring the response to osimertinib. In the same way, 
previous studies have reported similar results (18,19).
According to plasma genotyping, we were able to 
define three molecular patterns upon disease progression 
in patients treated with osimertinib, highlighting the 
importance heterogeneity in advanced disease. These 
patterns were also reported in a study cohort of 22 patients 
who became resistant to osimertinib and from whom cfDNA 
was collected during the phase I AURA study (7). Similarly, 
other studies have shown that the p.C797S mutation is 
always detected in conjunction with the p.T790M mutation 
as well as the original EGFR-sensitizing mutation (9,12,20). 
According to our data, these patterns may determine 
different prognoses. In our study, patients showing the 
“triplet pattern” (sensitizing+/T790M+/C797S+) tended 
to have better PFS and OS (P=0.1), suggesting that tumors 
that become resistant to osimertinib through p.T790M 
loss may have a poorer outcome. Likewise, Oxnard et al. 
reported that acquired resistance to osimertinib mediated 
by loss of the p.T790M mutation was associated with early 
treatment failure (21). However, despite its pertinence in 
this context, this observation requires confirmation in larger 
cohorts. NGS profiling of plasma samples has proved to be 
a valuable approach for identifying resistance mutations. 
In our hands, the activating mutations in codon 545 of the 
PIK3CA gene were frequently observed upon osimertinib 
progression. Likewise, other researchers have proposed 
that mutations in codon 545 of the PIK3CA gene constitute 
a common resistance mechanism of third-generation 
TKIs (22). Similarly, Yang et al. reported that mutations 
in PIK3CA potentially contribute to osimertinib resistance 
in patients without secondary EGFR mutations (23). 
In addition, we found the p.S464L mutation in the EGFR 
Figure 3 A 67-year-old male with metastatic lung adenocarcinoma treated with afatinib (AFA) as second-line treatment. Subsequently, 
the patient started treatment with osimertinib (OSI). Further disease progression was observed. The patient then began treatment with 
pemetrexed, which resulted in a slight decrease in ctDNA levels of the E545K mutation (PIK3CA). However, an increase in the mutant 
AF of the L858R mutation (EGFR) was observed during treatment, and PD was diagnosed soon after (denoted by a red triangle). ctDNA, 
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gene in the tumor of a patient treated with cetuximab plus 
afatinib prior to osimertinib therapy. Remarkably, this 
mutation has been reported in colorectal tumors that are 
refractory to cetuximab (24).
On the other hand, our results show that the efficacy 
of osimertinib in real-world practice was similar to that 
observed in clinical trials, with a favorable adverse effect 
profile. Similar results have recently been reported in a large 
sized real-world study (25). Strikingly, time on targeted 
therapy was longer in patients treated with the gefitinib 
+ osimertinib combination, than those who received one 
of the other two combinations, although no significant 
difference in PFS according to first-line TKI was found.
It is important to mention that the small sample size of 
the present study is an important limitation and therefore 
although our results are of particular interest they need to 
be tested in appropriately sized cohorts.
Conclusions
In summary, we report a comprehensive descriptive study of 
a real-world cohort of patients treated with osimertinib as 
second-line treatment. Analysis of ctDNA during the course 
of the disease revealed three molecular patterns that might 
confer different prognoses. Besides the p.C797S mutation, 
putative PIK3CA mutations might underlie osimertinib 
resistance in patients without secondary EGFR mutations.
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Supplementary 
Figure S1 OS (A) and PFS (B) according to the three molecular patterns: sensitizing+/T790M+/C797S+, sensitizing+/T790M+/C797S–, 
and sensitizing+/T790M–/C797S–. OS, overall survival; PFS, progression-free survival.
Figure S2 Time (months) since the earliest identification of an increment of the sensitizing mutation (orange bars), p.T790M (blue bars) 
and p.C797S (yellow bars) AFs and assessment of disease progression by CT-scan. CT, computed tomography.
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